share_log

Shattuck Labs | 10-Q: Q3 2024 Earnings Report

Shattuck Labs | 10-Q: Q3 2024 Earnings Report

Shattuck Labs | 10-Q：2024财年三季报
美股SEC公告 ·  2024/11/14 20:10

Moomoo AI 已提取核心信息

Shattuck Labs reported a Q3 2024 net loss of $16.7 million compared to $27.5 million in Q3 2023, with collaboration revenue increasing to $3.0 million from $0.7 million. Research and development expenses decreased 32.6% to $16.3 million, while cash and investments totaled $90.1 million as of September 30, 2024, expected to fund operations into 2027.The company announced a strategic restructuring to prioritize development of its DR3 program, including lead candidate SL-325 for inflammatory bowel disease. The restructuring involves discontinuing the SL-172154 program and reducing workforce by approximately 40%, with expected restructuring charges between $1.5-1.75 million to be recognized in Q4 2024.The company's lead program SL-325, a potential first-in-class DR3 antagonist antibody, is advancing in preclinical development with IND filing expected in Q3 2025. Additionally, Shattuck mutually agreed to terminate its collaboration agreement with Ono Pharmaceutical on September 30, 2024, after recognizing $5.4 million in revenue from the partnership during the first nine months of 2024.
Shattuck Labs reported a Q3 2024 net loss of $16.7 million compared to $27.5 million in Q3 2023, with collaboration revenue increasing to $3.0 million from $0.7 million. Research and development expenses decreased 32.6% to $16.3 million, while cash and investments totaled $90.1 million as of September 30, 2024, expected to fund operations into 2027.The company announced a strategic restructuring to prioritize development of its DR3 program, including lead candidate SL-325 for inflammatory bowel disease. The restructuring involves discontinuing the SL-172154 program and reducing workforce by approximately 40%, with expected restructuring charges between $1.5-1.75 million to be recognized in Q4 2024.The company's lead program SL-325, a potential first-in-class DR3 antagonist antibody, is advancing in preclinical development with IND filing expected in Q3 2025. Additionally, Shattuck mutually agreed to terminate its collaboration agreement with Ono Pharmaceutical on September 30, 2024, after recognizing $5.4 million in revenue from the partnership during the first nine months of 2024.
Shattuck Labs报告2024年第三季度净亏损为1670万美元，相较于2023年第三季度的2750万美元，合作营收从70万美元增长至300万美元。研发费用下降32.6%至1630万美元，截至2024年9月30日，现金及投资总额为9010万美元，预计可支撑运营至2027年。公司宣布进行战略重组，以优先发展其DR3项目，包括针对炎症性肠病的主要候选药物SL-325。重组涉及暂停SL-172154项目，并将 workforce 减少约40%，预计在2024年第四季度确认150-175万美元的重组费用。公司的主要项目SL-325，一种潜在的首创DR3拮抗抗体，正在进行临床前开发，预计将在2025年第三季度提交IND申请。此外，Shattuck与大冢药品于2024年9月30日共同达成协议，终止合作协议，在2024年前九个月中从合作中确认540万美元的营收。
Shattuck Labs报告2024年第三季度净亏损为1670万美元，相较于2023年第三季度的2750万美元，合作营收从70万美元增长至300万美元。研发费用下降32.6%至1630万美元，截至2024年9月30日，现金及投资总额为9010万美元，预计可支撑运营至2027年。公司宣布进行战略重组，以优先发展其DR3项目，包括针对炎症性肠病的主要候选药物SL-325。重组涉及暂停SL-172154项目，并将 workforce 减少约40%，预计在2024年第四季度确认150-175万美元的重组费用。公司的主要项目SL-325，一种潜在的首创DR3拮抗抗体，正在进行临床前开发，预计将在2025年第三季度提交IND申请。此外，Shattuck与大冢药品于2024年9月30日共同达成协议，终止合作协议，在2024年前九个月中从合作中确认540万美元的营收。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    科技巨头财报季如火如荼，英伟达压轴会表现如何？
    星期四， $亚马逊 (AMZN.US)$ 股价在公司报告第四季度调整后每股收益为1.86美元，预估为每股1.50美元，营业收入为1877.9亿，预估为1873.2亿后下跌。该公司预测第一季度的营业收入数字低于华尔街的预期，预测本季度最多为1550亿，而分析师希望为1580亿。 星 展开
    亚马逊盈利预告：猜测开盘价，获取奖励！